Recombinant human protein was used as the immunogen for the c-Myc antibody cocktail.
It recognizes a transcription factor of 64-67kDa, identified as c-myc. This mAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or over-expressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. Rearrangement of the MYC gene is found in 3% to 16% of diffuse large B-cell lymphoma (DLBCL s) and in nearly 100% of Burkitt lymphomas (BL). Identifying MYC status is important in establishing final diagnosis of DLBCL, BL, or B-cell lymphoma, with features intermediate between DLBCL and BL as well as in differential diagnoses of the lymphomas.
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Antibody Type:
Primary Antibody
Application Dilute:
Flow cytometry: 0.5-1ug/10 6 cells,Immunofluorescence: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Application Notes:
Optimal dilution of the c-Myc antibody cocktail should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min
* VAT and and shipping costs not included. Errors and price changes excepted
